Andersen-Tawil syndrome primary prevention

Andersen-Tawil syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Andersen-Tawil syndrome from other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Tertiary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Andersen-Tawil syndrome primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Andersen-Tawil syndrome primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Andersen-Tawil syndrome primary prevention
CDC on Andersen-Tawil syndrome primary prevention
Andersen-Tawil syndrome primary prevention in the news
Blogs on Andersen-Tawil syndrome primary prevention
Directions to Hospitals Treating Andersen-Tawil syndrome
Risk calculators and risk factors for Andersen-Tawil syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include Lifestyle modifications, carbonic anhydrase inhibitors using, potassium supplements and cardioverter-defibrillator.

Primary Prevention

Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include:

• Lifestyle modification if applicable
• Dietary modification if applicable
• Carbonic anhydrase inhibitors use like acetazolamide
  • Preferred regimen (1): Acetazolamide adults 125-1,000 mg daily, children 5-10 mg/kg/day
• Potassium supplements
  • Slow release potassium supplements may be helps with hypokalemic periodic paralysis
• Implantable cardioverter-defibrillator
  • Implantable cardioverter-defibrillator is an idle choice in patients with tachycardia-induced syncope

References

Template:WikiDoc Sources